Wells Fargo Maintains Overweight on Biomarin Pharmaceutical, Lowers Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal maintains an Overweight rating on Biomarin Pharmaceutical but lowers the price target from $115 to $90.
September 17, 2024 | 2:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wells Fargo has maintained its Overweight rating on Biomarin Pharmaceutical but has reduced the price target from $115 to $90, indicating a more cautious outlook.
The reduction in the price target from $115 to $90 by Wells Fargo suggests a more cautious outlook on Biomarin's future performance, which could lead to a short-term negative impact on the stock price. However, the maintained Overweight rating indicates continued confidence in the company's long-term potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100